Source link : https://newshealth.biz/health-news/post-marketing-studies-document-extra-vte-risk-for-baricitinib/
LONDON — Baricitinib (Olumiant) failed to show noninferiority to tumor necrosis factor (TNF) inhibitors for venous thromboembolism (VTE) risk in FDA-required postmarketing studies, a researcher reported here. In two large randomized trials with up to 6 years of follow-up in patients — ordered by the FDA as a condition of baricitinib’s approval in 2018 for […]
The post Post-Marketing Studies Document Extra VTE Risk for Baricitinib first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-07 15:14:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8